Published 2 days ago • loading... • Updated 2 days ago

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

2 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated23 hours agoBias Distribution

100% Center

100% Center

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in 2 days ago on Monday, March 9, 2026.

Sources are mostly out of (0)